These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35505478)

  • 21. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.
    Fitzpatrick C; Floyd K
    Pharmacoeconomics; 2012 Jan; 30(1):63-80. PubMed ID: 22070215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation.
    Menzies NA; Cohen T; Lin HH; Murray M; Salomon JA
    PLoS Med; 2012; 9(11):e1001347. PubMed ID: 23185139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using Top-down and Bottom-up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale.
    Cunnama L; Sinanovic E; Ramma L; Foster N; Berrie L; Stevens W; Molapo S; Marokane P; McCarthy K; Churchyard G; Vassall A
    Health Econ; 2016 Feb; 25 Suppl 1(Suppl Suppl 1):53-66. PubMed ID: 26763594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of the Xpert(®) MTB/RIF assay for diagnosing pulmonary tuberculosis comorbidity and multidrug-resistant TB in obstetrics and gynaecology inpatient wards at the University Teaching Hospital, Lusaka, Zambia.
    Bates M; Ahmed Y; Chilukutu L; Tembo J; Cheelo B; Sinyangwe S; Kapata N; Maeurer M; O'Grady J; Mwaba P; Zumla A
    Trop Med Int Health; 2013 Sep; 18(9):1134-1140. PubMed ID: 23834035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nature of drug resistance and predictors of multidrug-resistant tuberculosis among patients seen at the Philippine General Hospital, Manila, Philippines.
    Mendoza MT; Gonzaga AJ; Roa C; Velmonte MA; Jorge M; Montoya JC; Tan Torres T; Ong M; Barez MY; Ang CF
    Int J Tuberc Lung Dis; 1997 Feb; 1(1):59-63. PubMed ID: 9441060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expansion of social protection is necessary towards zero catastrophic costs due to TB: The first national TB patient cost survey in the Philippines.
    Florentino JL; Arao RML; Garfin AMC; Gaviola DMG; Tan CR; Yadav RP; Hiatt T; Morishita F; Siroka A; Yamanaka T; Nishikiori N
    PLoS One; 2022; 17(2):e0264689. PubMed ID: 35226705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of tuberculosis, multidrug resistant tuberculosis and associated risk factors among smear negative presumptive pulmonary tuberculosis patients in Addis Ababa, Ethiopia.
    Sinshaw W; Kebede A; Bitew A; Tesfaye E; Tadesse M; Mehamed Z; Yenew B; Amare M; Dagne B; Diriba G; Alemu A; Getahun M; Fikadu D; Desta K; Tola HH
    BMC Infect Dis; 2019 Jul; 19(1):641. PubMed ID: 31324227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costs of providing tuberculosis diagnosis and treatment services in Viet Nam.
    Minh HV; Mai VQ; Nhung NV; Hoi LV; Giang KB; Chung LH; Kien VD; Duyen NT; Ngoc NB; Anh TT; Phuong TB; Ngan TT; Khanh PH
    Int J Tuberc Lung Dis; 2017 Sep; 21(9):1035-1040. PubMed ID: 28826454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-optimization in the treatment of multidrug resistant tuberculosis in Nigeria.
    Musa BM; John D; Habib AG; Kuznik A
    Trop Med Int Health; 2016 Feb; 21(2):176-82. PubMed ID: 26610176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathways to multidrug-resistant tuberculosis diagnosis and treatment initiation: a qualitative comparison of patients' experiences in the era of rapid molecular diagnostic tests.
    Naidoo P; van Niekerk M; du Toit E; Beyers N; Leon N
    BMC Health Serv Res; 2015 Oct; 15():488. PubMed ID: 26511931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-cost survey for tuberculosis in the context of patient-pathway modelling.
    Tomeny EM; Mendoza VL; Marcelo DB; Barrameda AJD; Langley I; Abong JM; Dalay VB; Yu CY; Squire SB
    Int J Tuberc Lung Dis; 2020 Apr; 24(4):420-427. PubMed ID: 32317067
    [No Abstract]   [Full Text] [Related]  

  • 33. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
    Laurence YV; Griffiths UK; Vassall A
    Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.
    Chatla C; Jaju J; Achanta S; Samyuktha R; Chakramahanti S; Purad C; Chepuri R; Nair SA; Parmar M
    Indian J Tuberc; 2018 Jul; 65(3):218-224. PubMed ID: 29933863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-consequence analysis of ambulatory clinic- and home-based multidrug-resistant tuberculosis management models in Eswatini.
    Peresu E; De Graeve D; Heunis JC; Kigozi NG
    PLoS One; 2024; 19(4):e0301507. PubMed ID: 38564589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implementation and Operational Research: Clinical Impact of the Xpert MTB/RIF Assay in Patients With Multidrug-Resistant Tuberculosis.
    Padayatchi N; Naidu N; Yende-Zuma N; OʼDonnell MR; Naidoo K; Augustine S; Zumla A; Loveday M
    J Acquir Immune Defic Syndr; 2016 Sep; 73(1):e1-7. PubMed ID: 27509173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Xpert® MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania.
    Pimkina E; Zablockis R; Nikolayevskyy V; Danila E; Davidaviciene E
    Respir Med; 2015 Nov; 109(11):1484-9. PubMed ID: 26403251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of an indigenous assay for rapid molecular detection of rifampicin resistance in presumptive multidrug-resistant pulmonary tuberculosis patients.
    Gomathi NS; Singh M; Myneedu VP; Chauhan DS; Tripathy S; Sarin R; Mohan A; Bhatnagar A; Khangembam JS; Kannan T; V Rao MV; Logani J; Dey B; Gangakhedkar RR; Swaminathan S; Singh UB
    Indian J Med Res; 2020 Nov; 152(5):482-489. PubMed ID: 33707390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of the Xpert MTB/RIF test on the time to MDR-TB treatment initiation in a rural setting: a cohort study in South Africa's Eastern Cape Province.
    Iruedo J; O'Mahony D; Mabunda S; Wright G; Cawe B
    BMC Infect Dis; 2017 Jan; 17(1):91. PubMed ID: 28109255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of improvements in diagnosis and treatment accessibility for tuberculosis control in India.
    Suen SC; Bendavid E; Goldhaber-Fiebert JD
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1115-24, i-xv. PubMed ID: 26260835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.